← All companies
PVLA
Palvella Therapeutics, Inc.
$140.78
-9.41 -6.27%
Key statistics
from XBRL data in SEC filingsMarket cap
$2.02B
Revenue (TTM)
$1.35M
Net income (TTM)
-$49.3M
EPS (TTM)
$-4.17
P/E ratio
—
Dividend yield
—
Free cash flow
-$25.2M
Cash
$206M
Total assets
$264M
Gross margin
—
52-week range
$36.00 – $161.38
Recent SEC filings
40 most recentAnnual, quarterly & current reports
8-K
Other events
Jul 14, 2026
8-K
Director or officer change
Jun 30, 2026
8-K
Director or officer change; Shareholder vote results
Jun 16, 2026
8-K
Other events
May 20, 2026
8-K
Other events
May 15, 2026
8-K
Other events
May 13, 2026
8-K
Results of operations (earnings release); Regulation FD disclosure
May 7, 2026
10-Q
Quarter ended 2026-03-31
May 7, 2026
8-K
Director or officer change
Apr 13, 2026
8-K
Other events
Apr 7, 2026
10-K
Fiscal year ended 2025-12-31
Mar 31, 2026
8-K
Results of operations (earnings release); Regulation FD disclosure
Mar 31, 2026
8-K
Entered a material agreement
Feb 26, 2026
8-K
Results of operations (earnings release)
Feb 24, 2026
8-K
Regulation FD disclosure
Feb 24, 2026
8-K
Other events
Feb 24, 2026
8-K
Other events
Jan 29, 2026
8-K
Other events
Jan 12, 2026
8-K
Regulation FD disclosure; Other events
Dec 15, 2025
10-Q
Quarter ended 2025-09-30
Nov 12, 2025
8-K
Results of operations (earnings release); Regulation FD disclosure
Nov 10, 2025
8-K
Regulation FD disclosure; Other events
Nov 5, 2025
8-K
Regulation FD disclosure
Sep 24, 2025
8-K
Regulation FD disclosure
Sep 3, 2025
10-Q
Quarter ended 2025-06-30
Aug 14, 2025
8-K
Results of operations (earnings release); Regulation FD disclosure
Aug 14, 2025
8-K
Shareholder vote results
Jun 11, 2025
10-Q
Quarter ended 2025-03-31
May 15, 2025
8-K
Results of operations (earnings release); Regulation FD disclosure
May 15, 2025
10-K
Fiscal year ended 2024-12-31
Mar 31, 2025
8-K
Results of operations (earnings release); Regulation FD disclosure
Mar 31, 2025
8-K
Regulation FD disclosure
Mar 4, 2025
8-K
Regulation FD disclosure
Jan 13, 2025
8-K
Entered a material agreement; Completed an acquisition or disposition; Unregistered sale of equity; Modified rights of security holders; Change in control; Director or officer change; Amended charter or bylaws; Item 5.05; Item 5.06; Other events
Dec 16, 2024
8-K
Modified rights of security holders; Director or officer change; Amended charter or bylaws; Shareholder vote results; Other events
Dec 12, 2024
8-K
Shareholder vote results; Other events
Dec 3, 2024
10-Q
Quarter ended 2024-09-30
Nov 13, 2024
8-K
Other events
Oct 3, 2024
10-Q
Quarter ended 2024-06-30
Aug 14, 2024
8-K
Entered a material agreement; Unregistered sale of equity; Modified rights of security holders; Amended charter or bylaws
Aug 8, 2024